Subsidiary of Johnson & Johnson, Centocor is a biotechnology company that was founded in Philadelphia in 1979 with an initial goal of developing new diagnostic assays using monoclonal antibody technology.
In 1982 Centocor developed their first product approved by the U.S. Food and Drug Administration (FDA) — a diagnostic test used to detect the rabies virus, and in that same year transitioned into a publicly traded company. Subsequently, the company moved to a larger facility in Malvern, Pennsylvania (a northwest suburb of Philadelphia). In 1984, Centocor opened an overseas plant in Leiden, the Netherlands.
Eighteen years after its foundation, (in 1997), Centocor achieved its first year of operating profitability. In 1998, Centocor divested itself of its diagnostic division and launched its top-selling monoclonal antibody Remicade (infliximab) for its first FDA approved indication in Crohn's Disease.
In 1999, Centocor became a wholly owned subsidiary of Johnson & Johnson, the worldwide manufacturer and marketer of healthcare products. Subsequently, Remicade's market has expanded with approvals for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, and pediatric Crohn's disease. Remicade was approved for plaque psoriasis in September 2006.
Centocor also markets ReoPro (abciximab), a biologic agent indicated as an adjunct to coronary angioplasty (PTCA).
Since being acquired by Johnson and Johnson, Centocor has increased its annual sales from approximately $500 million to more than $2 billion. During the same period, research and development investment increased from $75 million to more than $300 million.
In 2004 Centocor purchased a new manufacturing plant in St. Louis, Missouri, and is currently opening a new manufacturing facility in County Cork, Ireland. The Dutch plant has been expanded substantially with a $250 million investment in additional production facilities, which were opened in 2006.
|
|
|
501-1,000 employees
View all Centocor employees
|
|
Biotechnology
|
|
, US
|
|
1979
|
|
Biotechnology From R&D To Manufacturing And Marketing
|
Lu Cheng Hong Yu is the CEO of Centocor. To contact Lu Cheng Hong Yu email at [email protected].
The decision makers in Centocor are Alina March, Ben Bulthuis, Charles Goochee, etc. Click to Find Centocor decision makers emails.
Centocor specializes in biotechnology products, particularly those developed through monoclonal antibody technology. The company focuses on creating innovative diagnostic assays and therapeutic solutions for various medical conditions, including autoimmune diseases, cancer, and infectious diseases. Their product range includes both diagnostic tests and biopharmaceuticals aimed at improving patient outcomes.
Centocor adheres to stringent quality control measures throughout the entire product lifecycle, from research and development to manufacturing and marketing. The company follows Good Manufacturing Practices (GMP) and conducts rigorous testing to ensure that all products meet regulatory standards. Additionally, Centocor invests in advanced technologies and processes to maintain the highest levels of quality and safety in its biopharmaceutical offerings.
Centocor primarily serves the healthcare and pharmaceutical industries. The company collaborates with healthcare providers, researchers, and other stakeholders to develop and deliver innovative solutions that address unmet medical needs. Their focus on biotechnology allows them to contribute significantly to the fields of diagnostics and therapeutics, impacting various sectors including oncology, immunology, and infectious disease management.
Yes, Centocor offers custom biopharmaceutical development services. The company works closely with partners to create tailored solutions that meet specific therapeutic needs. This includes assistance with the design, development, and manufacturing of monoclonal antibodies and other biologics. Centocor's expertise in biotechnology allows them to provide comprehensive support throughout the development process.
Research and development (R&D) is a cornerstone of Centocor's operations. The company invests heavily in R&D to innovate and improve its product offerings. By leveraging cutting-edge technologies and scientific advancements, Centocor aims to discover new therapeutic targets and develop effective treatments. Their R&D efforts are focused on addressing complex medical challenges and enhancing patient care through biotechnology.
Healthcare professionals can access Centocor's diagnostic assays through various channels, including direct partnerships with healthcare institutions, distributors, and online platforms. Centocor provides comprehensive training and support to ensure that healthcare providers can effectively utilize their diagnostic products. For specific inquiries or to learn more about product availability, professionals are encouraged to contact Centocor directly or visit their official website.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.